Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.

The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many people, despite the fact that there is little supporting, comparable, replicated scientific study. Stem cell therapy is being studied.

This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.

Administration of high doses of intravenous corticosteroids, such as methylprednisolone, is the routine therapy for acute relapses. This is administered over a period of three to five days, and has a well-established efficacy in promoting a faster recovery from disability after an attack. There is however insufficient evidence to indicate any significant impact on long-term disability of corticosteroid treatments. Steroids administered orally have a similar effectiveness and safety profile at treating MS symptoms as intravenous treatment. Consequences of severe attacks which do not respond to corticosteroids might be treated by plasmapheresis.

High dosage intravenous corticosteroids or plasmapheresis, designated for individuals not responding to steroids, make up the majority of acute management; Symptomatic management: Individuals with multiple sclerosis (MS) experience a range of symptoms, such as cognitive decline, discomfort, exhaustion, urinary problems, and stiffness. Both pharmaceutical and non-pharmacological approaches are used to address these symptoms. The management of MS symptoms requires a comprehensive and interdisciplinary approach from patients; illness-modifying therapies (DMTs): These medications act as moderators of illness, lowering the risk of relapses and slowing the disease's course.

As of 2020^[update], several disease-modifying treatments have been approved by regulatory agencies of different countries, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) of the Japanese Ministry of Health, Labour and Welfare.

Medications approved by the FDA include: interferons beta-1a and beta-1b; monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatiramer acetate, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, and diroximel fumarate. Siponimod was approved in March 2019. Cladribine was approved in March 2019. Ozanimod was approved in March 2020.